



# GLAND PHARMA LIMITED

November 04, 2022

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Disclosure of Related Party Transactions for the half-year ended September 30, 2022**

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find enclosed the details on Related Party Transactions for the half year ended September 30, 2022; prepared in accordance with the format specified by SEBI vide circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021.

This is for your information and records.

Yours truly,

**For Gland Pharma Limited**

**P Sampath Kumar**  
**Company Secretary and Compliance Officer**

Encl: As mentioned above

**GLAND PHARMA LIMITED**

Disclosure of related party transactions for the half-year ended September 30, 2022

(Rs. In million)

S.No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at March 31, 2022)	Closing balance (As at September 30, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Gland Pharma Limited		Gland Pharma International Pte Ltd.		Subsidiary	Sale of goods	3,000.00	606.97	-	609.79	-	-	-	-	-	-		
2	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Advance for supply of goods	-	-	(7.49)	(8.54)	-	-	-	-	-	-		
3	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Sale of goods	2,000.00	901.37	353.89	633.42	-	-	-	-	-	-		
4	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Sale of service	271.32	99.70	-	101.69	-	-	-	-	-	-		
5	Gland Pharma Limited		Jaingsu Wambang Helios International Trade Co. Ltd.		Fellow subsidiary	Advance for supply of goods	-	-	-	(0.03)	-	-	-	-	-	-		
6	Gland Pharma Limited		Jaingsu Wambang Helios International Trade Co. Ltd.		Fellow subsidiary	Sale of goods	50.00	8.66	-	-	-	-	-	-	-	-		
7	Gland Pharma Limited		Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.		Fellow subsidiary	Reimbursement of expense	NA	-	0.50	-	-	-	-	-	-	-		
8	Gland Pharma Limited		Tridem Pharma SAS		Fellow subsidiary	Sale of goods	1,500.00	10.87	10.15	-	-	-	-	-	-	-		
9	Gland Pharma Limited		Jaingsu Wambang Biopharmaceutical Company Limited		Fellow subsidiary	Purchase of raw material	4,312.00	730.81	328.65	121.33	-	-	-	-	-	-		
10	Gland Pharma Limited		Srinivas Sadu		Key management personnel	Remuneration	70.38	34.31	(2.59)	(7.76)	-	-	-	-	-	-		
11	Gland Pharma Limited		Ravi Shekhar Mitra		Key management personnel	Remuneration	20.01	9.51	(0.70)	(2.10)	-	-	-	-	-	-		
12	Gland Pharma Limited		Satyanarayana Murthy Chavali		Key management personnel	Sitting fee	0.30	0.30	-	(0.10)	-	-	-	-	-	-		
13	Gland Pharma Limited		Satyanarayana Murthy Chavali		Key management personnel	Commission	2.50	1.25	(2.25)	(1.25)	-	-	-	-	-	-		
14	Gland Pharma Limited		Yiu Kwan Stanley Lau		Key management personnel	Sitting fee	0.30	0.30	-	(0.14)	-	-	-	-	-	-		
15	Gland Pharma Limited		Yiu Kwan Stanley Lau		Key management personnel	Commission	4.57	2.44	(3.14)	(2.44)	-	-	-	-	-	-		
16	Gland Pharma Limited		Udo J. Vetter		Key management personnel	Sitting fee	0.30	0.30	-	(0.10)	-	-	-	-	-	-		
17	Gland Pharma Limited		Udo J. Vetter		Key management personnel	Commission	2.50	1.25	(1.72)	(1.25)	-	-	-	-	-	-		
18	Gland Pharma Limited		Essaji Goolam Vahanvati		Key management personnel	Sitting fee	0.30	0.20	-	(0.10)	-	-	-	-	-	-		
19	Gland Pharma Limited		Essaji Goolam Vahanvati		Key management personnel	Commission	2.50	1.25	(2.25)	(1.25)	-	-	-	-	-	-		
20	Gland Pharma Limited		Nainalal Kidwai		Key management personnel	Sitting fee	0.30	0.30	-	(0.10)	-	-	-	-	-	-		
21	Gland Pharma Limited		Nainalal Kidwai		Key management personnel	Commission	10.00	5.00	(9.00)	(5.00)	-	-	-	-	-	-		
22	Gland Pharma Limited		P. Sampath Kumar		Key management personnel	Remuneration	5.10	2.51	(0.15)	(0.46)	-	-	-	-	-	-		
	<b>Total</b>						<b>11,252.38</b>	<b>2,417.29</b>	<b>663.76</b>	<b>1,435.64</b>								

**Notes**

- Amount in bracket denotes credit balance.
- The value of transactions approved, in case of omnibus approval granted by the Audit Committee, are for the financial year 2022-23
- PAN details are not included in the above format as per the guidance note for related party transactions dated April 25, 2022, issued by the Stock exchanges.
- All above transactions are in the ordinary course of business and on arms' length basis. All outstanding balances are to be settled in cash and are unsecured.
- The remuneration to key managerial person does not include the provision made for gratuity and compensated absences, as they are on actuarial basis for the Company as a whole.

For GLAND PHARMA LIMITED

  
P. SAMPATH KUMAR  
Company Secretary